Benefits of Limited Use of a Tourniquet Combined With Intravenous Tranexamic Acid During Total Knee Arthroplasty

  • Ochsner Journal
  • December 2016,
  • 16
  • (4)
  • 443-449;

Abstract

Background: Blood loss during total knee arthroplasty (TKA) may require blood transfusions that are associated with increased risk, morbidity, and cost. Multiple techniques exist to reduce blood loss in TKA, including the use of a tourniquet and tranexamic acid (TXA). While multiple studies suggest that TXA is effective in reducing blood loss, the use of a tourniquet is more controversial. We studied the combined effect of TXA with a limited-use tourniquet on blood loss and complications in the setting of primary TKA.

Methods: A retrospective review of a prospectively gathered arthroplasty database from a single institution was performed. We compared our limited-use cohort data with the published results of randomized controlled trials evaluating the effectiveness of tourniquets used during the entire TKA procedure.

Results: Fifty-one procedures from our institution's database met the inclusion criteria. TXA (administered in a single 15-mg/kg dose) with limited tourniquet use (a mean duration of 26.3 minutes) resulted in an average intraoperative estimated blood loss of 94.7 mL. The mean decrease in hemoglobin from the preprocedure baseline to postoperative day 1 was 2.6 ± 0.9 g/dL (P<0.001), and only 2 of the 51 procedures required a blood transfusion. When compared to recent randomized controlled trials, the 51 procedures demonstrated lower levels of blood loss, similar operative time, and no increase in morbidity or mortality.

Conclusion: Our study results suggest that using TXA in combination with a tourniquet during the cementation portion only of a TKA provides a reasonable operative time and low intraoperative blood loss without increasing perioperative morbidity or complications.

Keywords

INTRODUCTION

Total knee arthroplasty (TKA) is among the most commonly performed elective procedures in the United States.1 Its prevalence has increased dramatically during the past several decades because of increases in obesity, the size of the aging population, and utilization.1 The desire to stay active among members of the modern population may be responsible for the rise in per capita utilization. TKA may be associated with significant blood loss for which blood transfusion might be necessary.2 Transfusion rates as high as 60% have been reported.1 Allogeneic blood transfusion, despite current testing parameters, carries significant potential risks1,3,4 and costs.1,5 Risks include mismatch attributable to clerical error, infection, and immunologic reactions caused by the transfusion or contaminants.1,3,4 Costs associated with TKA-related intraoperative blood loss and allogeneic transfusions include the costs of the blood units, of longer hospital stays, and of readmissions for transfusion-related complications.1,5

A pneumatic tourniquet is commonly used during TKA to reduce intraoperative blood loss and to improve visualization.1,2,6-8 The pneumatic tourniquet has also been shown to reduce operative time and to improve cement interdigitation.2,6-8 A 2009 survey of the members of the American Association of Hip and Knee Surgeons reported that 95% used a tourniquet during TKA.9 However, the clinical role of the tourniquet in TKA remains controversial2,8,10,11 because of the potential deleterious effects of prolonged pneumatic tourniquet use2,8,11-19 that can be devastating.1,2,8,11,12,17-32 Intraoperatively, the use of a tourniquet during trial reduction and patellofemoral tracking has been associated with an increased risk of lateral release, secondary to a tethered quadriceps mechanism.2,13-15 Postoperatively, limb pain,2 swelling,12 stiffness,8,19 delay of muscle-power recovery,12 subcutaneous limb fat necrosis,2,16 and wound hematoma leading to persistent wound drainage and subsequent increased infection risk2,31 have all been reported. Less common complications associated with prolonged pneumatic tourniquet use during TKA include nerve palsy mediated or modulated by compression neuropraxia,8,11,20,21,32,33 compartment syndrome,12,33 rhabdomyolysis,2,8,24 renal failure,8,24 direct vascular injury,11,22,26-28 deep vein thrombosis (DVT),2,8,11,25,27,30 pulmonary embolism (PE),1,8,11,23,25,29 acute pulmonary edema, and cardiac arrest immediately following tourniquet release.8,17-19 Last, prolonged tourniquet use during TKA may interfere with postoperative functional recovery and affect overall patient knee range of motion and clinical success.8,11,17-19

While some studies have shown that a tourniquet is effective in reducing intraoperative blood loss,30,34,35 others have failed to demonstrate this benefit.10,36,37

Tranexamic acid (TXA), a synthetic lysine analogue and competitive inhibitor of plasminogen at its lysine-binding site for fibrin,38,39 has been used successfully in numerous nonorthopedic surgical procedures to decrease blood loss.40-48 In the United States, initial interest in the use of TXA in the field of joint arthroplasty focused on primary and revision total hip arthroplasty46,47,49-51 because of the high potential for blood loss during these procedures. After demonstrating a significant decrease in blood loss and need for blood transfusion46,47,51 with primary and revision total hip arthroplasty procedures, TXA became commonly used in TKA.52,53

The literature is largely unclear regarding best-practice use of the pneumonic tourniquet and TXA.9,34-37,46-48,51-58 Consequently, the goal of this investigation was to determine whether the limited use of a pneumatic tourniquet in conjunction with the use of TXA would alter operative time, intraoperative blood loss, transfusion rate, and complication rates when compared with the use of a pneumatic tourniquet throughout the procedure.

METHODS

Patients

After Institutional Review Board approval was obtained, a search of the prospectively gathered arthroplasty database was conducted at the participating institution. All adult patients who underwent routine primary unilateral TKA (current procedural terminology [CPT] code 27447) by the senior author (A.D.R.) between April 30, 2013, and December 8, 2014, for osteoarthritis (OA) or rheumatoid arthritis (RA) were identified for inclusion in this retrospective cohort study. Patients who had undergone revision TKA, distal third femoral replacement TKA, or same-setting bilateral TKA; patients requiring computer assist or other electronic devices; and patients who had undergone previous intraarticular or periarticular open reduction and internal fixation were not included. Our search revealed a total of 70 patients.

Patients having preoperative gross deformities, severe contractures, or constrained TKA—a total of 21 patients—were excluded. A total of 51 knees, 29 right and 22 left, in 49 patients met the inclusion criteria. Two patients received bilateral knee arthroplasty in separate procedures.

All patients had their TKA performed by the senior author (A.D.R.) under general anesthesia and received a single dose of TXA, 15 mg/kg intravenously. All of the procedures were done through a midline skin incision and medial parapatellar arthrotomy. Tourniquet use was limited to the period of cementation. In all patients, the tourniquet was inflated after the extremity was exsanguinated, just prior to cementation, and deflated when the bone cement had cured. Intraoperative blood loss was estimated by addition of the volume of blood noted on the sponges to the volume collected in the suction canisters and subtraction of the amount of irrigation fluid used. Suction drains, cell savers, and autologous blood were not used. To further characterize postprocedural blood loss, hemoglobin levels were measured preprocedure and on postoperative day (POD) 1.

Data Collection

We individually reviewed patient medical records and operative reports. Data collected for the study included the anesthesia technique, TXA dose and route of administration, tourniquet inflation duration and pressure, operative time (from incision to completion of wound closure), intraoperative blood loss, hemoglobin levels (preoperatively and on POD 1), length of stay, and number of units of packed red blood cells transfused. All complications were noted, including surgical-site infections, delayed wound healing, readmission within 30 days for surgical complications, DVT, and PE. Patients were screened for DVT and PE only if clinically indicated.

Historical Control Selection

Electronic databases (PubMed, MEDLINE, and Embase) were searched by 2 independent researchers (Y.A.M. and A.D.R.) to identify studies published from January 2009 to June 2015. The keywords used in the search were total knee arthroplasty or total knee replacement and blood loss, tourniquet, and randomized controlled trial (RCT). Reference lists of the relevant papers were thoroughly searched for any further relevant studies. Only studies including a minimum of 25 patients in each arm were included. Eight RCTs that included the use of a tourniquet met the inclusion criteria and were included in the analysis from which root studies were reviewed and raw data were extracted.

Statistical Analysis

The statistical program SPSS v.19 (IBM) was used to analyze the data. Basic descriptive statistics are reported as means ± SD in addition to the median, minimal, and maximal values for continuous variables, and proportions and frequencies are reported for categorical variables. Paired t tests were used to examine changes in hemoglobin levels at POD 1 compared to preprocedure hemoglobin level. A P value <0.05 was used to determine statistical significance.

RESULTS

Patient demographics and comorbidities are described in Table 1. The average age of the patients at time of surgery was 65 ± 9 years (range, 50-83 years). A total of 51 procedures/knees in 49 patients (20 males and 29 females) were included in the investigation. The majority of procedures (50 of 51) were for the treatment of OA, with 1 procedure related to RA. We examined the demographics of our patient cohort in relation to published comparison studies that included patients for whom the tourniquet was inflated throughout the procedure, from incision to wound closure (Table 2).18,33,37,58-62 The patient characteristics in the published studies were comparable to the patient characteristics in our cohort.

View this table:
Table 1.

Patient Demographics and Comorbidities

View this table:
Table 2.

Demographics of Patients Receiving Limited Tourniquet Use Plus Tranexamic Acid During Total Knee Arthroplasty in Relation to Historical Comparison Studies

Data on the mean duration of procedure and tourniquet inflation time for our study cohort are presented in Table 3. Our operative variables and results were also comparable to published controls (Tables 4 and 5). Our mean duration of procedure was 116 minutes, which is within the range reported in the historical comparison studies (70.0-120.8 minutes). Our mean intraoperative estimated blood loss, a less precise measure, was 94.7 mL ± 48.5 mL, and this value is lower than the blood loss reported in all of the published RCTs used for comparison, except for the study published by Tai et al62 who reported a mean intraoperative blood loss of 25.6 ± 30.9 mL (Table 5).

View this table:
Table 3.

Procedure Characteristics

View this table:
Table 4.

Procedure Characteristics in Our Study Cohort in Relation to Historical Comparison Studies

View this table:
Table 5.

Complications in Our Study Cohort in Relation to Historical Comparison Studies

In our cohort, the mean decrease in hemoglobin from the preprocedure baseline to POD 1 was 2.8 g/dL ± 0.9 g/dL with hemoglobin levels at POD 1 (11.5 g/dL ± 1.4 g/dL) significantly decreased in comparison to baseline values (14.1 g/dL ± 1.2 g/dL, P<0.001) (Figure). Hemoglobin values on discharge were not significantly different than those measured on POD 1. The mean hemoglobin drop in the published comparison studies ranged from 1.9-3.4 mg/dL. This change is similar to the mean hemoglobin drop of 2.8 mg/dL noted in our study on POD 1; however, the timing of these published levels varied in some instances beyond POD 1.

Mean hemoglobin preprocedure, on postoperative day 1, and on discharge. *The mean decrease in hemoglobin from the preprocedure baseline to postoperative day 1 was 2.6 ± 0.9 g/dL (P<0.001).
Figure 1.

Mean hemoglobin preprocedure, on postoperative day 1, and on discharge. *The mean decrease in hemoglobin from the preprocedure baseline to postoperative day 1 was 2.6 ± 0.9 g/dL (P<0.001).

Of our 51 procedures, only 2 (3.9%) required blood transfusions during the perioperative period, with each patient receiving 2 units each. No surgical-site infections were reported in our patient cohort. One patient developed a PE after surgery. No patients required readmission for surgery-related postoperative complications or surgical revision.

DISCUSSION

The results of this investigation revealed that the use of TXA in combination with a tourniquet for only cementation provided reasonable operative time and low intraoperative blood loss without increasing perioperative morbidity or complications.

Our study findings concur with findings published by Tarwala et al33 in that the use of limited tourniquet along with TXA in the performance of TKA is as effective as using a tourniquet throughout the entire procedure as it relates to operative time, intraoperative blood loss, and need for blood transfusion. Two metaanalyses of randomized studies comparing tourniquet use throughout an entire case vs no tourniquet at all found differences only in total blood loss.2,63 More recently, 2 studies comparing the use of a tourniquet just for cementation of the implants with tourniquet use during the entire operation found no important clinical differences between the 2 methods.33,58

Our study has several limitations. First, it is a retrospective review. Second, we reviewed only 51 knee operations all performed by a single surgeon. Third, the majority of our patients were obese; therefore, our results may not be applicable to all populations. Finally, the study has no true control group to provide baseline blood loss levels for TKA without a tourniquet and without TXA.

From 1999-2009, the reported number of TKA cases performed annually in the United States doubled.64 Such an increase may be at least partially attributed to rising obesity rates, as well as to improved imaging and longer life expectancy.65,66 Increasing numbers of patients who require TKA and the high economic burden of this procedure will require techniques such as we have described for surgical and anesthetic management.67-72

CONCLUSION

Our investigation results demonstrate that using TXA in combination with a tourniquet for only cementation provides reasonable operative time and low intraoperative blood loss without increasing perioperative morbidity or complications.

This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care, Medical Knowledge, and Practice-Based Learning and Improvement.

ACKNOWLEDGMENTS

The authors have no financial or proprietary interest in the subject matter of this article.

REFERENCES

  1. 1
    ↵
    LevineBRHaughomBStrongBHellmanMFrankRM. Blood management strategies for total knee arthroplasty. J Am Acad Orthop Surg. 2014 6; 22 6: 361- 371. doi: 10.5435/JAAOS-22-06-361. 24860132
    CrossRefPubMed
  2. 2
    ↵
    TaiTWLinCJJouIMChangCWLaiKAYangCY. Tourniquet use in total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2011 7; 19 7: 1121- 1130. doi: 10.1007/s00167-010-1342-7. 21161177
    CrossRefPubMed
  3. 3
    ↵
    KirkleySACowlesJPellegriniVDHarrisCMBoydADBlumbergN. Blood transfusion and total joint replacement surgery: T helper 2 (TH2) cytokine secretion and clinical outcome. Transfus Med. 1998 9; 8 3: 195- 204. 9800291
    Google ScholarCrossRefPubMedWeb of Science
  4. 4
    ↵
    KleinHG. How safe is blood, really? Biologicals. 2010 1; 38 1: 100- 104. doi: 10.1016/j.biologicals.2009.10.008. 20074975
    CrossRefPubMedWeb of Science
  5. 5
    ↵
    SpahnDR. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology. 2010 8; 113 2: 482- 495. doi: 10.1097/ALN.0b013e3181e08e97. 20613475
    CrossRefPubMedWeb of Science
  6. 6
    ↵
    SmithTOHingCB. Is a tourniquet beneficial in total knee replacement surgery? A meta-analysis and systematic review. Knee. 2010 3; 17 2: 141- 147. doi: 10.1016/j.knee.2009.06.007. 19616954
    CrossRefPubMedWeb of Science
  7. 7
    WhiteheadDJMacDonaldSJ. TKA sans tourniquet: let it bleed: opposes. Orthopedics. 2011 9 9; 34 9: e497- e499. doi: 10.3928/01477447-20110714-44. 21902143
    CrossRefPubMed
  8. 8
    ↵
    ZhangWLiNChenSTanYAl-AidarosMChenL. The effects of a tourniquet used in total knee arthroplasty: a meta-analysis. J Orthop Surg Res. 2014 3 6; 9 1: 13 doi: 10.1186/1749-799X-9-13. 24602486
    CrossRefPubMed
  9. 9
    ↵
    BerryDJBozicKJ. Current practice patterns in primary hip and knee arthroplasty among members of the American Association of Hip and Knee Surgeons. J Arthroplasty. 2010 9; 25 6 Suppl: 2- 4. doi: 10.1016/j.arth.2010.04.033. 20580196
    CrossRefPubMedWeb of Science
  10. 10
    ↵
    TetroAMRudanJF. The effects of a pneumatic tourniquet on blood loss in total knee arthroplasty. Can J Surg. 2001 2; 44 1: 33- 38. 11220796
    Google ScholarPubMedWeb of Science
  11. 11
    ↵
    Lohmann-JensenRHolsgaard-LarsenAEmmeluthCOvergaardSJensenC. The efficacy of tourniquet assisted total knee arthroplasty on patient-reported and performance-based physical function: a randomized controlled trial protocol. BMC Musculoskelet Disord. 2014 3 29; 15: 110 doi: 10.1186/1471-2474-15-110. 24678741
    CrossRefPubMed
  12. 12
    ↵
    WakaiAWinterDCStreetJTRedmondPH. Pneumatic tourniquets in extremity surgery. J Am Acad Orthop Surg. 2001 Sep-Oct; 9: 345- 351. 11575914
    Google ScholarPubMed
  13. 13
    ↵
    KomatsuTIshibashiYOtsukaHNagaoATohS. The effect of surgical approaches and tourniquet application on patellofemoral tracking in total knee arthroplasty. J Arthroplasty. 2003 4; 18 3: 308- 312. 12728422
    Google ScholarCrossRefPubMed
  14. 14
    LombardiAVJrBerendKRMalloryTHDoddsKLAdamsJB. The relationship of lateral release and tourniquet deflation in total knee arthroplasty. J Knee Surg. 2003 10; 16 4: 209- 214. 14584833
    Google ScholarPubMed
  15. 15
    ↵
    HustedH Toftgaard Jensen T. Influence of the pneumatic tourniquet on patella tracking in total knee arthroplasty: a prospective randomized study in 100 patients. J Arthroplasty. 2005 9; 20 6: 694- 697. 16139703
    Google ScholarCrossRefPubMed
  16. 16
    ↵
    TamvakopoulosGSTomsAPGlasgowM. Subcutaneous thigh fat necrosis as a result of tourniquet control during total knee arthroplasty. Ann R Coll Surg Engl. 2005 9; 87 5: W11- W13. 16402457
    Google ScholarCrossRefPubMed
  17. 17
    ↵
    ZhangFJXiaoYLiuYBTianXGaoZG. Clinical effects of applying a tourniquet in total knee arthroplasty on blood loss. Chin Med J (Engl). 2010 11; 123 21: 3030- 3033. 21162951
    Google ScholarPubMed
  18. 18
    ↵
    LedinHAspenbergPGoodL. Tourniquet use in total knee replacement does not improve fixation, but appears to reduce final range of motion. Acta Orthop. 2012 10; 83 5: 499- 503. doi: 10.3109/17453674.2012.727078. 22974220
    CrossRefPubMedWeb of Science
  19. 19
    ↵
    LiuDGrahamDGilliesKGilliesRM. Effects of tourniquet use on quadriceps function and pain in total knee arthroplasty. Knee Surg Relat Res. 2014 12; 26 4: 207- 213. doi: 10.5792/ksrr.2014.26.4.207. 25505702
    CrossRefPubMed
  20. 20
    ↵
    NewmanRJ. Metabolic effects of tourniquet ischaemia studied by nuclear magnetic resonance spectroscopy. J Bone Joint Surg Br. 1984 5; 66 3: 434- 440. 6725357
    Google ScholarPubMed
  21. 21
    ↵
    SapegaAAHeppenstallRBChanceBParkYSSokolowD. Optimizing tourniquet application and release times in extremity surgery. A biochemical and ultrastructural study. J Bone Joint Surg Am. 1985 2; 67 2: 303- 314. 3968122
    Google ScholarAbstract/Full TextPubMed
  22. 22
    ↵
    IrvingGANoakesTD. The protective role of local hypothermia in tourniquet-induced ischaemia of muscle. J Bone Joint Surg Br. 1985 3; 67 2: 297- 301. 3156860
    Google ScholarPubMedWeb of Science
  23. 23
    ↵
    McGrathBJHsiaJEpsteinB. Massive pulmonary embolism following tourniquet deflation. Anesthesiology. 1991 3; 74 3: 618- 620. 2001041
    Google ScholarCrossRefPubMedWeb of Science
  24. 24
    ↵
    PalmerSHGrahamG. Tourniquet-induced rhabdomyolysis after total knee replacement. Ann R Coll Surg Engl. 1994 11; 76 6: 416- 417. 7702328
    Google ScholarPubMed
  25. 25
    ↵
    Abdel-SalamAEyresKS. Effects of tourniquet during total knee arthroplasty. A prospective randomised study. J Bone Joint Surg Br. 1995 3; 77 2: 250- 253. 7706340
    Google ScholarPubMed
  26. 26
    ↵
    KumarSNChapmanJARawlinsI. Vascular injuries in total knee arthroplasty. A review of the problem with special reference to the possible effects of the tourniquet. J Arthroplasty. 1998 2; 13 2: 211- 216. 9526217
    Google ScholarCrossRefPubMedWeb of Science
  27. 27
    ↵
    WakankarHMNichollJEKokaRD'ArcyJC. The tourniquet in total knee arthroplasty. A prospective, randomised study. J Bone Joint Surg Br. 1999 1; 81 1: 30- 33. 10067997
    Google ScholarCrossRefPubMed
  28. 28
    ↵
    SmithDEMcGrawRWTaylorDCMasriBA. Arterial complications and total knee arthroplasty. J Am Acad Orthop Surg. 2001 Jul-Aug; 9 4: 253- 257. 11476535
    Google ScholarCrossRefPubMed
  29. 29
    ↵
    NishiguchiMTakamuraNAbeYKonoMShindoHAoyagiK. Pilot study on the use of tourniquet: a risk factor for pulmonary thromboembolism after total knee arthroplasty? Thromb Res. 2005; 115 4: 271- 276. 15668186
    Google ScholarCrossRefPubMed
  30. 30
    ↵
    FukudaAHasegawaMKatoKShiDSudoAUchidaA. Effect of tourniquet application on deep vein thrombosis after total knee arthroplasty. Arch Orthop Trauma Surg. 2007 10; 127 8: 671- 675. 17102960
    Google ScholarPubMed
  31. 31
    ↵
    ButtUAhmadRAsprosDBannisterGC. Factors affecting wound ooze in total knee replacement. Ann R Coll Surg Engl. 2011 1; 93 1: 54- 56. doi: 10.1308/003588410X12771863937124. 20836920
    CrossRefPubMed
  32. 32
    ↵
    OlivecronaCBlomfeldtRPonzerSStanfordBRNilssonBY. Tourniquet cuff pressure and nerve injury in knee arthroplasty in a bloodless field: a neurophysiological study. Acta Orthop. 2013 4; 84 2: 159- 164. doi: 10.3109/17453674.2013.782525. 23485070
    CrossRefPubMed
  33. 33
    ↵
    TarwalaRDorrLDGilbertPKWanZLongWT. Tourniquet use during cementation only during total knee arthroplasty: a randomized trial. Clin Orthop Relat Res. 2014 1; 472 1: 169- 174. doi: 10.1007/s11999-013-3124-2. 23836239
    CrossRefPubMed
  34. 34
    ↵
    HarveyEJLeclercJBrooksCEBurkeDL. Effect of tourniquet use on blood loss and incidence of deep vein thrombosis in total knee arthroplasty. J Arthroplasty. 1997 4; 12 3: 291- 296. 9113543
    Google ScholarCrossRefPubMedWeb of Science
  35. 35
    ↵
    VandenbusscheEDuranthonLDCouturierMPidhorzLAugereauB. The effect of tourniquet use in total knee arthroplasty. Int Orthop. 2002; 26 5: 306- 309. 12378360
    Google ScholarCrossRefPubMed
  36. 36
    ↵
    AgliettiPBaldiniAVenaLMAbbateRFediSFalcianiM. Effect of tourniquet use on activation of coagulation in total knee replacement. Clin Orthop Relat Res. 2000 2; (371):169-177.
    Google Scholar
  37. 37
    ↵
    LiBWenYWuHQianQLinXZhaoH. The effect of tourniquet use on hidden blood loss in total knee arthroplasty. Int Orthop. 2009 10; 33 5: 1263- 1268. doi: 10.1007/s00264-008-0647-3. 18751703
    CrossRefPubMed
  38. 38
    ↵
    PrenticeCR. Basis of antifibrinolytic therapy. J Clin Pathol Suppl (R Coll Pathol). 1980; 14: 35- 40. 6159375
    Google ScholarPubMed
  39. 39
    ↵
    MannucciPM. Hemostatic drugs. N Engl J Med. 1998 7 23; 339 4: 245- 253. 9673304
    Google ScholarCrossRefPubMedWeb of Science
  40. 40
    ↵
    Shore-LessersonLReichDLVela-CantosFAmmarTErginMA. Tranexamic acid reduces transfusions and mediastinal drainage in repeat cardiac surgery. Anesth Analg. 1996 7; 83 1: 18- 26. 8659732
    Google ScholarCrossRefPubMedWeb of Science
  41. 41
    DalmauASabatéAAcostaF Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg. 2000 7; 91 1: 29- 34. 10866882
    Google ScholarCrossRefPubMedWeb of Science
  42. 42
    IckxBEvan der LindenPJMelotC Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. Transfusion. 2006 4; 46 4: 595- 605. 16584436
    Google ScholarCrossRefPubMed
  43. 43
    HenryDACarlessPAMoxeyAJ Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD001886.
    Google Scholar
  44. 44
    ColominaMJBagóJVidalXMoraLPelliséF. Antifibrinolytic therapy in complex spine surgery: a case-control study comparing aprotinin and tranexamic acid. Orthopedics. 2009 2; 32 2: 91. 19301800
    Google ScholarPubMed
  45. 45
    HenryDCarlessPFergussonDLaupacisA. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ. 2009 1 20; 180 2: 183- 193. doi: 10.1503/cmaj.081109. 19050037
    CrossRefAbstract/Full TextPubMed
  46. 46
    ↵
    SukeikMAlshrydaSHaddadFSMasonJM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011 1; 93 1: 39- 46. doi: 10.1302/0301-620X.93B1.24984. 21196541
    CrossRefPubMed
  47. 47
    ↵
    WindTCBarfieldWRMoskalJT. The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty. J Arthroplasty. 2014 2; 29 2: 387- 389. doi: 10.1016/j.arth.2013.05.026. 23790499
    CrossRefPubMed
  48. 48
    ↵
    KagomaYKCrowtherMADouketisJBhandariMEikelboomJLimW. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009 3; 123 5: 687- 696. doi: 10.1016/j.thromres.2008.09.015. 19007970
    CrossRefPubMedWeb of Science
  49. 49
    ↵
    GillJBRosensteinA. The use of antifibrinolytic agents in total hip arthroplasty: a meta-analysis. J Arthroplasty. 2006 9; 21 6: 869- 873. 16950041
    Google ScholarCrossRefPubMedWeb of Science
  50. 50
    GillJBChaseERosensteinA. The use of tranexamic acid in revision total hip arthroplasty: a pilot study. Curr Orthop Pract. 2009 4; 20 2: 152- 156. doi: 10.1097/BCO.0b013e318191ebc0.
    CrossRef
  51. 51
    ↵
    KazemiSMMosaffaFEajaziA The effect of tranexamic acid on reducing blood loss in cementless total hip arthroplasty under epidural anesthesia. Orthopedics. 2010 1; 33 1: 17 doi: 10.3928/01477447-20091124-30. 20055345
    CrossRefPubMed
  52. 52
    ↵
    EubanksJD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010 3; 18 3: 132- 138. 20190103
    Google ScholarCrossRefPubMed
  53. 53
    ↵
    YangZGChenWPWuLD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am. 2012 7 3; 94 13: 1153- 1159. doi: 10.2106/JBJS.K.00873. 22623147
    CrossRefAbstract/Full TextPubMed
  54. 54
    BarsoumWKKlikaAKMurrayTGHigueraCLeeHHKrebsVE. Prospective randomized evaluation of the need for blood transfusion during primary total hip arthroplasty with use of a bipolar sealer. J Bone Joint Surg Am. 2011 3 16; 93 6: 513- 518. doi: 10.2106/JBJS.J.00036. 21411700
    CrossRefAbstract/Full TextPubMed
  55. 55
    SeoJGMoonYWParkSHKimSMKoKR. The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2013 8; 21 8: 1869- 1874. doi: 10.1007/s00167-012-2079-2. 22729012
    CrossRefPubMed
  56. 56
    SehatKREvansRNewmanJH. How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account. Knee. 2000 7 1; 7 3: 151- 155. 10927208
    Google ScholarCrossRefPubMedWeb of Science
  57. 57
    MarulandaGAKrebsVEBierbaumBE Hemostasis using a bipolar sealer in primary unilateral total knee arthroplasty. Am J Orthop (Belle Mead NJ). 2009 12; 38 12: E179- E183. 20145794
    Google ScholarPubMed
  58. 58
    ↵
    FanYJinJSunZ The limited use of a tourniquet during total knee arthroplasty: a randomized controlled trial. Knee. 2014 12; 21 6: 1263- 1268. doi: 10.1016/j.knee.2014.08.002. 25212990
    CrossRefPubMed
  59. 59
    EjazALaursenACKappelA Faster recovery without the use of a tourniquet in total knee arthroplasty. Acta Orthop. 2014 8; 85 4: 422- 426. doi: 10.3109/17453674.2014.931197. 24954487
    CrossRefPubMed
  60. 60
    ChenSLiJPengHZhouJFangHZhengH. The influence of a half-course tourniquet strategy on peri-operative blood loss and early functional recovery in primary total knee arthroplasty. Int Orthop. 2014 2; 38 2: 355- 359. doi: 10.1007/s00264-013-2177-x. 24258152
    CrossRefPubMed
  61. 61
    MittalRKoVAdieS Tourniquet application only during cement fixation in total knee arthroplasty: a double-blind, randomized controlled trial. ANZ J Surg. 2012 6; 82 6: 428- 433. doi: 10.1111/j.1445-2197.2012.06083.x. 22571508
    CrossRefPubMed
  62. 62
    ↵
    TaiTWChangCWLaiKALinCJYangCY. Effects of tourniquet use on blood loss and soft-tissue damage in total knee arthroplasty: a randomized controlled trial. J Bone Joint Surg Am. 2012 12 19; 94 24: 2209- 2215. doi: 10.2106/JBJS.K.00813. 23318610
    CrossRefAbstract/Full TextPubMed
  63. 63
    ↵
    AlcelikIPollockRDSukeikMBettany-SaltikovJArmstrongPMFismerP. A comparison of outcomes with and without a tourniquet in total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. J Arthroplasty. 2012 3; 27 3: 331- 340. doi: 10.1016/j.arth.2011.04.046. 21944371
    CrossRefPubMedWeb of Science
  64. 64
    ↵
    KurtzSOngKLauEMowatFHalpernM. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007 4; 89 4: 780- 785. 17403800
    Google ScholarCrossRefAbstract/Full TextPubMed
  65. 65
    ↵
    LosinaEKatzJN. Total knee arthroplasty on the rise in younger patients: are we sure that past performance will guarantee future success? Arthritis Rheum. 2012 2; 64 2: 339- 341. doi: 10.1002/art.33371. 22252374
    CrossRefPubMedWeb of Science
  66. 66
    ↵
    MehrotraCRemingtonPLNaimiTSWashingtonWMillerR. Trends in total knee replacement surgeries and implications for public health, 1999-2000. Public Health Rep. 2005 May-Jun; 120 3: 278- 282. 16134568
    Google ScholarCrossRefPubMed
  67. 67
    ↵
    FleischutPMEskreis-WinklerJMGaber-BaylisLK Variability in anesthetic care for total knee arthroplasty: an analysis from the anesthesia quality institute. Am J Med Qual. 2015 Mar-Apr; 30 2: 172- 179. doi: 10.1177/1062860614525989. 24627358
    CrossRefPubMed
  68. 68
    EscobarAQuintanaJMBilbaoA Development of explicit criteria for prioritization of hip and knee replacement. J Eval Clin Pract. 2007 6; 13 3: 429- 434. 17518810
    Google ScholarCrossRefPubMed
  69. 69
    FrankelLSanmartinCConner-SpadyB Osteoarthritis patients' perceptions of “appropriateness” for total joint replacement surgery. Osteoarthritis Cartilage. 2012 9; 20 9: 967- 973. doi: 10.1016/j.joca.2012.05.008. 22659599
    CrossRefPubMedWeb of Science
  70. 70
    Total knee replacements on the rise, despite high costs. Harv Health Lett. 2012 12; 38 2: 8.
    Google Scholar
  71. 71
    BhandariMSmithJMillerLEBlockJE. Clinical and economic burden of revision knee arthroplasty. Clin Med Insights Arthritis Musculoskelet Disord. 2012; 5: 89- 94. doi: 10.4137/CMAMD.S10859. 23239930
    CrossRefPubMed
  72. 72
    ↵
    RobinsonJCPozenATsengSBozicKJ. Variability in costs associated with total hip and knee replacement implants. J Bone Joint Surg Am. 2012 9 19; 94 18: 1693- 1698. 22878562
    Google ScholarCrossRefAbstract/Full TextPubMed
Loading
Loading
Loading
PDF
Back to top

In this issue

Ochsner Journal

Vol. 16, Issue 4

Dec 2016

Table of Contents Index by author

Jump to section

Keywords

Arthroplasty–replacement–knee, blood transfusion, tourniquets, tranexamic acid